Clinical Trial TitleA phase 1/2a, open-label, multicenter, dose escalation study to assess the safety, pharmacokinetics and pharmacodynamics profile of a long-acting recombinant Factor VIIa (MOD-5014) in adult men with hemophilia A or B, with or without inhibitors.
Clinical Trial Protocol Description:
This study will consist of 3 time periods: a screening period of up to 28 days, 1 day of drug administration and 29 days of follow-up.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Have moderate to severe hemophilia A or B.
- Are male at least 18 yeras of age.
This is a partial list of elgibility requirements.